# Effect of SRT2104 on Endotoxin-induced Inflammation

> **NCT01014117** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 41 (actual)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** Placebo
- **DRUG:** SRT2104

## Key facts

- **NCT ID:** NCT01014117
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-09
- **Primary completion:** 2010-05-10
- **Final completion:** 2010-05-10
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01014117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01014117, "Effect of SRT2104 on Endotoxin-induced Inflammation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01014117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*